• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    6 Ways ERP Systems Help Medical Device Manufacturers Manage Risk and Profitability

    Machining & Laser Processing Have Huge Parts to Play in Medtech Manufacturing

    Medtech R&D Teams Must Be Creative & Resilient to Survive

    Struggling Suppliers in Electronics Manufacturing Services (EMS)

    Deep (Brain) Thoughts with Medtronic's Neuromodulation President
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    Konica Minolta Introduces Mobile X-Ray Systems to Latin America

    NIH MedTech Program Aims to Develop Neurological Treatment Tech

    Formula Plastics Appoints Bill Gerard as President

    First Patient Undergoes Kidney Stone Removal Using MONARCH Platform

    Michael Duqette Named COO at Producto Group
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    6 Ways ERP Systems Help Medical Device Manufacturers Manage Risk and Profitability

    Machining & Laser Processing Have Huge Parts to Play in Medtech Manufacturing

    Medtech R&D Teams Must Be Creative & Resilient to Survive

    Struggling Suppliers in Electronics Manufacturing Services (EMS)

    Deep (Brain) Thoughts with Medtronic's Neuromodulation President
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Deducing the Dual Reality of Elizabeth Holmes

    The Return of the AdvaMed MedTech Conference…Live!

    Material Matters: New Materials Call for New Thinking

    5 Ways to Maintain a Talent-Centric Mindset, Even During Economic Uncertainty

    The Changing Face of UK Medical Device Regulations: Most Recent Update
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Fusion Biotec Inc.

    Medbio LLC

    Arthur G. Russell Co. Inc., The

    Paragon Medical

    JBC Technologies
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Onshoring Medical Device Manufacturing Can Strengthen Supply Chains

    How Artificial Intelligence Can Combat Key Issues Impacting Healthcare

    Why Advanced Sensors Are Crucial Within Medical Pumps

    How Artificial Intelligence Could Help Prevent 80% of Chronic Diseases

    4 Ways to Use Injection Molding in Medical Device Manufacturing
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Fusion Biotec Inc.

    Medbio LLC

    Arthur G. Russell Co. Inc., The

    Paragon Medical

    JBC Technologies
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    BD to Acquire Bard for $24 Billion

    Will create highly differentiated company focused on delivering healthcare solutions to improve clinical, economic outcomes.

    BD to Acquire Bard for $24 Billion
    Related Content
    • MedTech Innovator Names the Finalists for the Title of MedTech Innovator 2021
    • Babson Diagnostics Raises $31 Million in Series B Funding
    • Medical Devices Market to Top $671.49 Billion by 2027
    • Vicarious Surgical Business Combination with D8 Holdings Approved
    • FDA Issues EUA for BD Veritor At-Home Covid-19 Test
    PR Newswire04.23.17
    BD (Becton, Dickinson and Company) a global medical technology company, and C. R. Bard Inc., a medical technology developer in the fields of vascular, urology, oncology and surgical specialty products, announced a definitive agreement under which BD will acquire Bard for $317.00 per Bard common share in cash and stock, for a total consideration of $24 billion. The agreement has been unanimously approved by the Boards of Directors of both companies.
     
    The combination will create a highly differentiated medical technology company uniquely positioned to improve both the process of care and the treatment of disease for patients and healthcare providers. The transaction will build on BD's leadership position in medication management and infection prevention with an expanded offering of solutions across the care continuum. Additionally, Bard's strong product portfolio and innovation pipeline will increase BD's opportunities in fast-growing clinical areas, and the combination will enhance growth opportunities for the combined company in non-U.S. markets. 
     
    This financially compelling transaction will be immediately accretive and is expected to generate high-single digit accretion to adjusted earnings per share (EPS) in fiscal year 2019. Approximately $300 million of estimated annual, pre-tax, run-rate cost synergies are expected by fiscal year 2020. Separately, BD also expects to benefit from revenue synergies beginning in fiscal year 2019. The transaction is expected to improve BD's gross margins by approximately 300 basis points in fiscal year 2018, increase BD's earnings per share growth trajectory to the mid-teens, and generate strong cash flow.
     
    Vince Forlenza, BD's chairman and chief executive officer, said, "Combining with Bard will accelerate our ability to offer more comprehensive, clinically relevant solutions to customers and patients around the globe, creating a strong partner for healthcare providers who are increasingly focused on delivering better outcomes at a lower total cost. Our two purpose-driven organizations are well-aligned strategically, sharing a strong track record of performance and a deep commitment to addressing unmet needs in today's challenging healthcare environment. We expect the transaction to contribute meaningfully to BD's plans for revenue growth and margin expansion, and generate outstanding value both near- and long-term for shareholders. I am excited to welcome Bard's talented employees to our strong and dedicated team as we bring together two companies with such complementary capabilities, values and strong reputations for delivering superior results."
     
    Tim Ring, Bard's chairman and chief executive officer, said, "We are confident that this combination will deliver meaningful benefits for customers and patients as we see opportunities to leverage BD's leadership, especially in medication management and infection prevention. We also believe that we can expand our access to customers and patients through BD's strategic selling capabilities, and that our fast-growing portfolio in emerging markets can significantly benefit from their well-established international commercial infrastructure. Our two companies share the conviction that a product leadership strategy focused on unmet needs and improved outcomes that provide economic value to the global healthcare system will provide long-term shareholder returns.

    John Weiland, Bard's vice-chairman, president and chief operating officer, added, "BD and Bard share a common purpose with highly compatible organizations. We are very proud of the business and culture we have built over 110 years, focused on quality, integrity, innovation and service. We have long had great respect for BD and find in them a similarly strong, results-oriented culture that prioritizes execution and long-term value creation. In addition to significant benefits for our customers, patients, and shareholders, we believe this combination will provide our employees with new and exciting opportunities as part of a highly competent, dynamic global organization. We look forward to this next chapter in our company's great history."

    Strategic Highlights
    Will create new opportunities to build on BD's leadership position in medication management and infection prevention with an expanded offering of solutions across the care continuum.
     
    • Will bring together highly complementary product sets to create unmatched solutions for customers, enhancing growth opportunities for the combined company.
    • By combining Bard's strong leadership position and innovation pipeline in fast-growing vascular access segments—PICCs (peripherally inserted central catheters), midlines and drug delivery ports—with BD's leadership and innovation in IV drug preparation, dispensing, delivery and administration, the new company will be better positioned to provide end-to-end medication management solutions across the care continuum.
    • Will further expand BD's leadership in infection prevention, with offerings positioned to address 75 percent of the most costly and frequent healthcare associated infections (HAIs). Through the combined solutions set, the new company will have a more comprehensive, clinically relevant offering to address Surgical Site Infections (SSIs) and Catheter-Related Blood Stream Infections (CRBSIs).
     
    Bard's strong product portfolio and innovation pipeline will increase BD's opportunities in fast growing clinical areas, including peripheral vascular therapy, oncology and bio-surgery.
     
    • Bard's clinically differentiated offerings create more meaningful scale and relevance for BD in high-growth categories of oncology and surgery.
    • Bard will expand BD's focus on the treatment of disease states beyond diabetes to include peripheral vascular disease, urology, hernia and cancer.
     
    BD's global capabilities and infrastructure will further accelerate the combined company's growth outside of the U.S., creating more opportunities for patients and clinicians around the world to benefit from BD's and Bard's product technology.
     
    • Together, BD and Bard will bring to market an expanded portfolio of clinically relevant products, with opportunities to drive near-term revenue synergies outside of the U.S.
    • Bard, which registered approximately 500 products internationally in 2016, has made significant progress expanding outside of the U.S. in recent years, particularly in emerging markets, where Bard is among the fastest growing medical technology companies.
    • Bard's strong presence in vascular access and surgery will also help drive sales of the highly complementary CareFusion portfolio outside of the U.S.
    • The combined company will have a large and growing presence in emerging markets, including $1 billion in annual revenue in China.
     
    Transaction Highlights
    Under the terms of the transaction, Bard common shareholders will be entitled to receive approximately $222.93 in cash and 0.5077 shares of BD stock per Bard share, or a total of value of $317.00 per Bard common share based on BD's closing price on April 21, 2017. At closing, Bard shareholders will own approximately 15 percent of the combined company. 
     
    BD expects to contribute approximately $1.7 billion of available cash to fund the transaction, along with, subject to market conditions, approximately $10 billion of new debt and approximately $4.5 billion of equity and equity linked securities issued to the market. Bard shareholders will also receive $8 billion of BD common stock. BD has also obtained fully committed bridge financing. At closing, BD estimates the combined company will have pro forma leverage of approximately 4.7x and is committed to deleveraging to below 3.0x leverage within three years of closing. BD expects to continue the suspension of its share repurchase program. BD is also committed to annual dividend increases while reinvesting in the business to continue to drive long-term growth. 
     
    The transaction is subject to regulatory and Bard shareholder approvals and customary closing conditions, and is expected to close in the fall of 2017.
     
    Integration Plans
    BD has a successful integration track record, as demonstrated by its 2015 acquisition and integration of CareFusion. BD has put in place a plan to ensure a seamless integration with Bard. A designated integration team, comprised of senior members of both organizations, will be led by Bill Tozzi, a seasoned BD executive who most recently served as worldwide president of the Medication and Procedural Solutions business and earlier was corporate controller for BD. At the closing of the transaction, Tim Ring, chairman and chief executive of Bard, and an additional Bard director, are expected to join the BD Board of Directors, which will be expanded by two directors.  BD is confident in its ability to achieve synergies as it brings together two world class companies and expects to offer opportunities for talented employees to become part of an even more dynamic global leader. 
     
    BD Organizational Update
    BD expects to create a third segment within the company—BD Interventional—where the Bard businesses will report both operationally and financially. BD is separately announcing today the appointment of Tom Polen, 43, currently executive vice president and president of the BD Medical Segment, as president of BD, effective immediately. In his new role, Mr. Polen will oversee BD's Medical and Life Sciences segments, as well as the new Interventional segment.
     
    Transaction Conference Call and Webcast Information
    BD and Bard will conduct a live conference call and webcast on April 24, 2017 at 8:00 a.m. (ET).  The webcast of the conference call, along with related slides, will be accessible through BD's and Bard's websites. The conference call will also be available for replay through BD's and Bard's websites, or at (800) 585-8367 (domestic) and (404) 537-3406 (international) through the close of business on May 1, 2017, confirmation number 13011331.
     
    BD Earnings Update
    BD's earnings conference call, previously scheduled for Thursday, May 4, 2017, has been rescheduled for Tuesday, May 2, 2017, at 8:00 a.m. (ET).  BD will issue a press release detailing the quarter's earnings earlier that morning.  The webcast of the conference call, along with related slides, will be accessible through BD's website at www.BD.com/investors and will be available for replay through Thursday, May 9, 2017.
     
    Bard Earnings Update
    Bard separately announced first quarter 2017 financial results, which are available on Bard's corporate website, and is canceling the previously scheduled earnings conference call on April 26, 2017.
     
    Advisors
    Perella Weinberg Partners LP is acting as lead financial advisor to BD. Citi is also serving as a financial advisor to BD and will be providing fully committed financing. Skadden, Arps, Slate, Meagher & Flom LLP provided legal counsel to BD. Goldman, Sachs & Co. served as financial advisor to Bard.  Wachtell, Lipton, Rosen & Katz served as legal advisor to Bard.
    Related Searches
    • medical
    • 2015
    • cancer
    • track
    Suggested For You
    MedTech Innovator Names the Finalists for the Title of MedTech Innovator 2021 MedTech Innovator Names the Finalists for the Title of MedTech Innovator 2021
    Babson Diagnostics Raises $31 Million in Series B Funding Babson Diagnostics Raises $31 Million in Series B Funding
    Medical Devices Market to Top $671.49 Billion by 2027 Medical Devices Market to Top $671.49 Billion by 2027
    Vicarious Surgical Business Combination with D8 Holdings Approved Vicarious Surgical Business Combination with D8 Holdings Approved
    FDA Issues EUA for BD Veritor At-Home Covid-19 Test FDA Issues EUA for BD Veritor At-Home Covid-19 Test
    Stanislav Glezer Joins Inogen as Chief Medical Officer Stanislav Glezer Joins Inogen as Chief Medical Officer
    BD Launches FACSymphony A1 Benchtop Cell Analyzer BD Launches FACSymphony A1 Benchtop Cell Analyzer
    BD Names Christopher DelOrefice as EVP and CFO BD Names Christopher DelOrefice as EVP and CFO
    Global Peripheral Intravenous Catheter Market to Reach $7.3B by 2027 Global Peripheral Intravenous Catheter Market to Reach $7.3B by 2027
    BD Acquires Velano Vascular BD Acquires Velano Vascular
    Global Enteral Feeding Devices Market to Reach $4.85 Billion by 2027 Global Enteral Feeding Devices Market to Reach $4.85 Billion by 2027
    Fluid Management System Market to be Worth $23.2 Billion By 2028 Fluid Management System Market to be Worth $23.2 Billion By 2028
    COVID-19 Sample Collection Kits Market to Reach $16.56B by 2028 COVID-19 Sample Collection Kits Market to Reach $16.56B by 2028
    Global Diabetes Care Devices Market to Garner $39.4B by 2027 Global Diabetes Care Devices Market to Garner $39.4B by 2027
    BD to Build $200 Million Manufacturing Facility in Zaragoza, Spain BD to Build $200 Million Manufacturing Facility in Zaragoza, Spain

    Related Breaking News

    • MedTech Innovator Names the Finalists for the Title of MedTech Innovator 2021

      MedTech Innovator Names the Finalists for the Title of MedTech Innovator 2021

      Attendees of The MedTech Conference, powered by AdvaMed, will vote for the Grand Prize winner.
      MedTech Innovator 09.21.21

    • Diagnostics
      Babson Diagnostics Raises $31 Million in Series B Funding

      Babson Diagnostics Raises $31 Million in Series B Funding

      Money will be used to help drive commercialization of customer-first, highly accessible diagnostic blood testing.
      Business Wire 09.20.21

    • Medical Devices Market to Top $671.49 Billion by 2027

      Medical Devices Market to Top $671.49 Billion by 2027

      Wearables and rising cases of chronic diseases will help fuel growth, industry data predicts.
      Precedence Research 09.16.21


    • Surgical
      Vicarious Surgical Business Combination with D8 Holdings Approved

      Vicarious Surgical Business Combination with D8 Holdings Approved

      Vicarious Surgical to debut on NYSE as disruptive next-gen surgical robotics company.
      Business Wire 09.16.21

    • Diagnostics
      FDA Issues EUA for BD Veritor At-Home Covid-19 Test

      FDA Issues EUA for BD Veritor At-Home Covid-19 Test

      The test does not require a prescription, a laboratory or a long wait for results.
      BD 08.26.21

    Loading, Please Wait..

    Trending
    • MO SCI Acquires Assets Of 3M’s Advanced Materials Business
    • CGM Devices Could Become Main Glucose Monitoring Solution In U.S.
    • Positive Long-Term Prospects For Japanese Diabetes Care Market
    • The Future Of Biomedical Engineering Advancements
    • 5 Ways Plastics Revolutionized The Healthcare Industry
    Breaking News
    • Konica Minolta Introduces Mobile X-Ray Systems to Latin America
    • NIH MedTech Program Aims to Develop Neurological Treatment Tech
    • Formula Plastics Appoints Bill Gerard as President
    • First Patient Undergoes Kidney Stone Removal Using MONARCH Platform
    • Michael Duqette Named COO at Producto Group
    View Breaking News >
    CURRENT ISSUE

    January/February 2023

    • Struggling Suppliers in Electronics Manufacturing Services (EMS)
    • Machining & Laser Processing Have Huge Parts to Play
    • Medtech R&D Teams Must Be Creative & Resilient to Survive
    • Medtronic Neuromodulation President, Nnamdi Njoku, Interview
    • 6 Ways ERP Systems Help Medical Device Manufacturers Manage Risk and Profitability
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    ADM Expands Production to Meet Demand for Probiotics
    Wiley’s Finest Debuts Peak DHA Featuring 600 mg of DHA and 300 mg of EPA
    FDA to Allow Qualified CVD Risk Reduction Claim for Cocoa Flavanols in High Flavanol Cocoa Powder
    Coatings World

    Latest Breaking News From Coatings World

    Personnel Changes at BASF
    Dr. Kurt Wood to Deliver Mattiello Memorial Lecture at ACA’s 2023 CoatingsTech Conference
    hubergroup Chemicals to Debut at the European Coatings Show
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Konica Minolta Introduces Mobile X-Ray Systems to Latin America
    NIH MedTech Program Aims to Develop Neurological Treatment Tech
    Formula Plastics Appoints Bill Gerard as President
    Contract Pharma

    Latest Breaking News From Contract Pharma

    ValiRx Signs Lease Deal with Nottingham Laboratories
    Civica Partners with Ypsomed for Insulin Injection Pen
    Charles River Laboratories Completes the Acquisition of SAMDI Tech
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Tree Hut Introduces Body Wash Line
    Zara Introduces Mini Artists—Beauty Products for Kids
    L’Oréal USA Taps Stephanie Kramer as Chief Human Resources Officer
    Happi

    Latest Breaking News From Happi

    FTC Extends Public Comment Period on Potential Updates to Green Guides
    Arm & Hammer Taps Dave & Jenny Marrs, TikTokers for Budget-Centered 'Give It The Hammer' Campaign
    Meaningful Beauty Age-Proof Hair Care System Now Available on Amazon
    Ink World

    Latest Breaking News From Ink World

    Siegwerk, Wildplastic, TU-Hamburg Partner on Deinking
    Brilliant Group and Terra Firm Launch Partnership
    hubergroup Chemicals Debuts at the European Coatings Show
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    The Oldham Group names Doug McClure technical sales rep
    Siegwerk partnership aims to improve plastic waste recyclability
    CELAB-Europe launches new web hub for liner recyclers
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Hospeco Offers TaskBrand Prep-Paint-Finish Wiping System
    Toray to Expand PPS Production in Korea
    Masque Bar Launches Compostable Sheet Masks
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    OSSIO Introduces Non-Permanent Compression Staple
    Dennis Jones Joins Intelivation Technologies as Manufacturing VP
    Jury Convicts Chiropractor, Orthopedic Surgeon in $31M Fraud Scheme
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Zebra Technologies Extends Partnership with the NFL
    OE-A at LOPEC – Printed Electronics Up Close
    Monthly Recap: LG OLED, Avery Dennison and JOLED Top This Month’s Stories

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login